Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
International Federation of Gynecology and Obstetrics(FIGO) stage IIIC-IVA, HGSOC Patients with Fagotti score ≥8
Adequate kidney function (blood creatinine 58-96 µmol/L)
Adequate haematological function (haemoglobin ≥110g/L, leucocytes ≥4.0×109/L, neutrophils ≥2.0×109/L, platelets≥100×109/L)
Adequate liver function (serum total bilirubin 3.4-22.2µmol/L, alanine aminotransferase (ALT) 7-40U/L, aspartate aminotransferase (AST) 13-35U/L, AST/ALT ≤1.5)
World Health Organization(WHO) score 0-2
expected lifespan\>12 weeks
You may not be if
Patients who had received chemotherapy, radiotherapy or any kind of targeted therapy
Complicated with any other known malignancies
Patients with poor cardiopulmonary function, which would limit compliance with study requirements
Clareo Health | Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial
